The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index; none of the 24 sources its claims cite is checked for support yet.
Pathogenic protein seeding in alzheimer disease and other neurodegenerative disorders
Open accessAbstract
The misfolding and aggregation of specific proteins is a seminal occurrence in a remarkable variety of neurodegenerative disorders. In Alzheimer disease (the most prevalent cerebral proteopathy), the two principal aggregating proteins are β‐amyloid (Aβ) and tau. The abnormal assemblies formed by conformational variants of these proteins range in size from small oligomers to the characteristic lesions that are visible by optical microscopy, such as senile plaques and neurofibrillary tangles. Pathologic similarities with prion disease suggest that the formation and spread of these proteinaceous lesions might involve a common molecular mechanism—corruptive protein templating. Experimentally, cerebral β‐amyloidosis can be exogenously induced by exposure to dilute brain extracts containing aggregated Aβ seeds. The amyloid‐inducing agent probably is Aβ itself, in a conformation generated most effectively in the living brain. Once initiated, Aβ lesions proliferate within and among brain regions. The induction process is governed by the structural and biochemical nature of the Aβ seed, as well as the attributes of the host, reminiscent of pathogenically variant prion strains. The concept of prionlike induction and spreading of pathogenic proteins recently has been expanded to include aggregates of tau, α‐synuclein, huntingtin, superoxide dismutase‐1, and TDP‐43, which characterize such human neurodegenerative disorders as frontotemporal lobar degeneration, Parkinson/Lewy body disease, Huntington disease, and amyotrophic lateral sclerosis. Our recent finding that the most effective Aβ seeds are small and soluble intensifies the search in bodily fluids for misfolded protein seeds that are upstream in the proteopathic cascade, and thus could serve as predictive diagnostics and the targets of early, mechanism‐based interventions. Establishing the clinical implications of corruptive protein templating will require further mechanistic and epidemiologic investigations. However, the theory that many chronic neurodegenerative diseases can originate and progress via the seeded corruption of misfolded proteins has the potential to unify experimental and translational approaches to these increasingly prevalent disorders. Ann Neurol 2011;70:532–540
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
This review argues that many neurodegenerative proteopathies, including Alzheimer’s disease, progress by prion-like corruptive protein templating, in which misfolded protein seeds induce and spread aggregation of Aβ, tau, α-synuclein, and other proteins. It synthesizes experimental seeding evidence and discusses implications for biomarkers, therapeutics, and possible iatrogenic transmission, while noting that clinical implications remain uncertain.
Key findings
- In Alzheimer’s disease, Aβ aggregation is implicated as an early trigger; cerebral Aβ deposition precedes clinical symptoms by a decade or more, and tauopathy correlates strongly with cognitive decline. Oligomeric Aβ, ranging from dimers to dodecamers or larger, may be more deleterious than histologically obvious plaques and cerebral amyloid angiopathy.
- Cerebral β-amyloidosis can be experimentally induced in APP-transgenic mice by intracerebral infusion of brain extracts containing minute amounts of aggregated Aβ. Evidence includes that seeding requires aggregated human-sequence Aβ, is impeded by anti-Aβ immunodepletion, is ineffective in non-transgenic mice, mirrors the donor deposit phenotype, and is abrogated by formic acid denaturation.
- The most potent Aβ seeds appear to be small and soluble, including proteinase K-sensitive species in the 100,000×g soluble fraction; sonication enhances seeding. In contrast, aggregated synthetic Aβ has not significantly induced cerebral Aβ deposition in APP-transgenic mice.
- Tau tangles can be exogenously induced by brain extract containing abnormal tau filaments in Alz17 mice, with time- and region-dependent spread; prion-like propagation has also been implicated for α-synuclein, SOD1, TDP-43, and polyglutamine aggregates. Human prion disease transmission has occurred in fewer than 700 known cases.
Methods
- Narrative review; no new primary data are reported. It synthesizes human neuropathology, genetics, imaging, and transgenic mouse/cell-culture seeding experiments.
- The main analysis is a conceptual synthesis of evidence for corruptive protein templating across Alzheimer’s disease, prion disease, tauopathies, synucleinopathies, amyotrophic lateral sclerosis/frontotemporal lobar degeneration, and Huntington’s disease.
- No systematic search strategy, meta-analysis, or quantitative pooling is described.
Limitations
- Stated: many questions remain, clinical implications are uncertain, and much research on this phenomenon is fragmentary. The paper also states that there is no direct evidence linking non-prion neurodegenerative diseases to seeds arising outside the central nervous system or taken up from the environment.
- Stated: final evidence is lacking that in vivo tau induction occurs via prion-like corruptive templating rather than, for example, activation of a signaling cascade; the mode of cell-to-cell transfer of aggregates is unclear. Transmission of non-prion proteopathies by tainted instruments is a theoretical possibility not demonstrated in humans.
- Evident: as a narrative review, it does not provide systematic search criteria, quantitative synthesis, or primary experimental validation, and some cited findings are described as in press or not fully detailed.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 24 cited sources checked · 0 supported · 0 flagged
In the paper
“Our recent finding that the most effective Aβ seeds are small and soluble”
§ Pathogenic Protein Seeding in Alzheimer’s Disease and Other Neurodegenerative Disorders > Abstract
What the sources say
- Not checked yetcites [54] Langer F Eisele YS Fritschi S Staufenbiel M Walker LC Jucker M Soluble Aβ seeds are potent inducers of cerebral β-amyloid deposition J Neuroscience 2011 in press PMC3229270 21994365 source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIn the paper
“Using a paradigm similar to in vivo Aβ-seeding, neurofibrillary (tau) tangles can be exogenously induced by the intracerebral infusion of brain extract containing abnormal tau filaments into mice bearing a human tau transgene63.”
§ Pathogenic Protein Seeding in Alzheimer’s Disease and Other Neurodegenerative Disorders > Induction and spread of tau filaments in experimental animals
What the sources say
- Not checked yetcites [63] Clavaguera F Bolmont T Crowther RA Transmission and spreading of tauopathy in transgenic mouse brain Nat Cell Biol 2009 11 909 13 19503072 PMC2726961 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The seeded proliferation of misfolded proteins, a concept that arose and evolved in the prion field, holds considerable explanatory power for the pathogenesis of many of the neurodegenerative diseases that afflict our burgeoning elderly population.”
§ Pathogenic Protein Seeding in Alzheimer’s Disease and Other Neurodegenerative Disorders > Conclusion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes? Based: unclearA conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“While the transmission of non-prion proteopathies by tainted instruments thus is a theoretical possibility, proof of such a phenomenon (which could be obscured by a protracted incubation period) has not been demonstrated in humans.”
§ Pathogenic Protein Seeding in Alzheimer’s Disease and Other Neurodegenerative Disorders > Clinical, Practical and Theoretical Implications
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIn the paper
“Experimentally, β-amyloid induction can be triggered in transgenic mice by intracerebrally implanted stainless steel wires coated with minute amounts of brain extract rich in aggregated Aβ52 (Fig 2).”
§ Pathogenic Protein Seeding in Alzheimer’s Disease and Other Neurodegenerative Disorders > Clinical, Practical and Theoretical Implications
What the sources say
- Not checked yetcites [52] Eisele YS Bolmont T Heikenwalder M Induction of cerebral beta-amyloidosis: intracerebral versus systemic Abeta inoculation Proc Natl Acad Sci U S A 2009 106 12926 31 19622727 PMC2722323 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesThe paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Once initiated, Aβ lesions proliferate within and among brain regions.”
§ Pathogenic Protein Seeding in Alzheimer’s Disease and Other Neurodegenerative Disorders > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIn the paper
“the (slight) risk of prion transmission by instruments used on patients with undiagnosed prion disease106”
§ Pathogenic Protein Seeding in Alzheimer’s Disease and Other Neurodegenerative Disorders > Clinical, Practical and Theoretical Implications
What the sources say
- Not checked yetcites [106] Ward HJ Everington D Croes EA Sporadic Creutzfeldt-Jakob disease and surgery: a case-control study using community controls Neurology 2002 59 543 8 12196646 source
Strength:plain· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesNone of the sources cited for this claim have been checked yet.
In the paper
“Experimentally, cerebral β-amyloidosis can be exogenously induced by exposure to dilute brain extracts containing aggregated Aβ seeds.”
§ Pathogenic Protein Seeding in Alzheimer’s Disease and Other Neurodegenerative Disorders > Abstract
What the sources say
- Not checked yetcites [49] Kane MD Lipinski WJ Callahan MJ Evidence for seeding of beta -amyloid by intracerebral infusion of Alzheimer brain extracts in beta -amyloid precursor protein-transgenic mice J Neurosci 2000 20 3606 11 10804202 PMC6772682 source
- Not checked yetcites [50] Walker LC Callahan MJ Bian F Durham RA Roher AE Lipinski WJ Exogenous induction of cerebral beta-amyloidosis in betaAPP-transgenic mice Peptides 2002 23 1241 7 12128081 source
- Not checked yetcites [51] Meyer-Luehmann M Coomaraswamy J Bolmont T Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host Science 2006 313 1781 4 16990547 source
- Not checked yetcites [52] Eisele YS Bolmont T Heikenwalder M Induction of cerebral beta-amyloidosis: intracerebral versus systemic Abeta inoculation Proc Natl Acad Sci U S A 2009 106 12926 31 19622727 PMC2722323 source
- Not checked yetcites [53] Watts JC Giles K Grillo SK Lemus A DeArmond SJ Prusiner SB Bioluminescence imaging of Abeta deposition in bigenic mouse models of Alzheimer’s disease Proc Natl Acad Sci U S A 2011 108 2528 33 21262831 PMC3038719 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesNone of the sources cited for this claim have been checked yet.
In the paper
“In cell culture, however, the prion-like propagation of α-synuclein lesions has been demonstrated80, 81”
§ Pathogenic Protein Seeding in Alzheimer’s Disease and Other Neurodegenerative Disorders > Induction and spread of protein aggregates linked to other neurodegenerative diseases
What the sources say
- Not checked yetcites [80] Desplats P Lee HJ Bae EJ Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein Proc Natl Acad Sci U S A 2009 106 13010 5 19651612 PMC2722313 source
- Not checked yetcites [81] Hansen C Angot E Bergstrom AL alpha-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells J Clin Invest 2011 121 715 25 21245577 PMC3026723 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The induction and proliferation of proteinaceous aggregates by corruptive protein templating appears to be a common feature of multiple, clinically diverse disorders, although many questions remain to be addressed (Table 1).”
§ Pathogenic Protein Seeding in Alzheimer’s Disease and Other Neurodegenerative Disorders > Clinical, Practical and Theoretical Implications
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Rests on an assumption: Findings from transgenic mouse and cell culture models of protein seeding are representative of the pathogenic process in human neurodegenerative diseases.
- Probably not a substantial claim. 2
- It may state two separate claims as one. 1
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The theoretical framework underlying this paradigm recently has expanded to include an extraordinary array of neurological and systemic disorders.”
§ Pathogenic Protein Seeding in Alzheimer’s Disease and Other Neurodegenerative Disorders > Conclusion
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the clinical implications remain uncertain”
§ Pathogenic Protein Seeding in Alzheimer’s Disease and Other Neurodegenerative Disorders > Conclusion
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
In the paper
“In AD, cerebral β-amyloid deposition begins in humans at least a decade prior to the onset of cognitive decline, and hence is an early and predictive indicator of the disease4.”
§ Pathogenic Protein Seeding in Alzheimer’s Disease and Other Neurodegenerative Disorders > Clinical, Practical and Theoretical Implications
What the sources say
- Not checked yetcites [4] Holtzman DM Morris JC Goate AM Alzheimer’s disease: the challenge of the second century Sci Transl Med 2011 3 77sr1 21471435 PMC3130546
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper relies on this without support.
Findings from transgenic mouse and cell culture models of protein seeding are representative of the pathogenic process in human neurodegenerative diseases.
“Establishing the clinical implications of corruptive protein templating will require further mechanistic and epidemiologic investigations.”
The paper relies on this without support.
Cerebral proteopathies are growing in prevalence.
“the growing prevalence of cerebral proteopathies necessitates a comprehensive quest”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“A synapse-centred hypothesis also does not preclude the spreading hypothesis [34, 66], which could be either a downstream pathological event or a potential trigger of Tau-related excitotoxicity and synaptic failure.”
From The new genetic landscape of Alzheimer’s disease: from amyloid cascade to genetically driven synaptic failure hypothesis? (2019) · cites this paper as [66]
In the citing paper
“The fact that the amyloid tap turns itself off before clinical changes appreciably manifest, we feel, also argues against the idea that Aβ perpetuates itself in a prion-like fashion [261].”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [261]
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedNeuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 3×
“Whereas the degree of tauopathy correlates strongly with cognitive decline in AD 6-8 , genetic, pathologic and biochemical evidence implicates the aggregation of A β as a critical, early trigger in the chain of events that leads to tauopathy, neuronal dysfunction and dementia 9 .”
BackgroundThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 1×
“In the brain, the a-synuclein–rich lesions that typify Lewy body disease/Parkinson disease first arise in the lower brainstem (notably the dorsal motor nucleus of the vagus nerve), and in the anterior olfactory nucleus and the olfactory bulb; they subsequently appear in a predictable sequence in mesencephalic and neoc…”
BackgroundSoluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490 · cited 2×
“Crosssectional autopsy studies indicate that b-amyloid (Ab) plaques (A) first appear in the neocortex, followed by the allocortex and finally subcortical regions.(21) In the brain, neurofibrillary tangles (B) occur first in the locus coeruleus and transentorhinal area and then spread to the amygdala and interconnected…”
BackgroundMethodSynapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model
Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S.-M., Iwata, N., Saido, T. C., Maeda, J., Suhara, T., Trojanowski, J. Q., & Lee, V. M.-Y. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.010 · Cited by 2,208
Buckner, R. L., Snyder, A. Z., Shannon, B. J., LaRossa, G., Sachs, R., Fotenos, A. F., Sheline, Y. I., Klunk, W. E., Mathis, C. A., Morris, J. C., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2177-05.2005 · Cited by 2,140
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 625
Wilson, D. L., Carreon, A., Chinnam, S., et al. (2024) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-024-01293-x · Cited by 2
“Measurement of the rate can then be used to fi ne-tune ambient conditions either to intervene in the fi brillation or to promote it (say, for biophysical studies) [9].”
Neuroinflammation in Age-Related Neurodegenerative Diseases
MacPherson, K. P., Rodrigues, M. E. D. S., Cintron, A. F., & Tansey, M. G. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811304-2.00016-x · Cited by 2
Calibration of Biophysical Models for tau-Protein Spreading in Alzheimer's Disease from PET-MRIPreprint
Scheufele, K., Subramanian, S., & Biros, G. (2020) · arXiv (Cornell University) · doi:10.48550/arxiv.2007.01236 · Cited by 5
“Tau aggregates are primarily found in the axon bundle and rapidly spread along neuronal pathways to distant locations, but also invade the extracellular space [19].”
BackgroundVesicular Transport and Amyloids: The Growing Relationship
Upadhyay, A. (2024) · Biologics · doi:10.3390/biologics4040023 · Cited by 1
“Evidence suggests that the pathological forms of tau can propagate from affected brain areas to the nearby healthy areas of the brain, resembling a mechanism often used by prion proteins [93,94].”
A peridynamic biochemo-mechanical model for Alzheimer’s Disease
Qiu, L., Wang, X., Wei, Z. C., & Tong, Q. (2025) · Engineering Analysis with Boundary Elements · doi:10.1016/j.enganabound.2025.106329 · Cited by 1
Tian, L., Zhang, B., Yang, X., Zhai, X., Gao, Y., Zhang, Y., Xie, X., Zhang, D., & Liang, C. (2025) · Springer eBooks · doi:10.1007/978-3-031-95878-6_11 · Cited by 1
Wu, K., Lee, S., Martínez-Serra, R., Zhang, L., Lynham, S., & Giese, K.-P. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-03905-x · Cited by 1
“Further, we used cortical neurons as amyloid pathology in AD commences in cortex [30].”
Amyloidy i prionoidy – czy jest już czas, żeby się obawiać?
Liberski, P. P. (2013) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 1
Candela, S., Giubilei, F., & Orzi, F. (2013) · PubMed · Cited by 1
Conformation-Dependent Antibodies as Tools for Characterization of Amyloid Protein Aggregates
Wu, J., & Breydo, L. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394431-3.00008-0 · Cited by 1
Misgeld, T., Lichtenthaler, S. F., & Dichgans, M. (2013) · EMBO Reports · doi:10.1038/embor.2013.70 · Cited by 1
Investigation of Lysozyme Refolding Using Ionic Liquids as Refolding Additives
Kaur, H. (2013) · Scholarship@Western (Western University) · Cited by 1
Hal, G. F. (2012) · Journal of Alzheimer’s Disease & Parkinsonism · doi:10.4172/2161-0460.1000e124 · Cited by 1
“An exclusive focus on such mechanisms has become prominent in recent reviews of this topic, at least with respect to tau protein [26,27,34,35] and is particularly notable in studies based on results from transgenic animal disease models in which intercellular tau transfer in situ can only be assessed indirectly [36,37…”
BackgroundAlzheimer's disease - neurological or psychiatric disorder?
Poalelungi, A., & Popescu, B. O. (2013) · Romanian Journal of Neurology · doi:10.37897/rjn.2013.1.1 · Cited by 1
Rüb, U., Vonsattel, J. P., Heinsen, H., & Korf, H. (2015) · Advances in anatomy, embryology and cell biology · doi:10.1007/978-3-319-19285-7_10 · Cited by 1
Ryadnov, M. G. (2013) · Royal Society of Chemistry eBooks · doi:10.1039/9781849737081-00079 · Cited by 1
Degeneration of Select Motor and Limbic Nuclei of the Thalamus in Huntington’s Disease (HD)
Rüb, U., Vonsattel, J. P., Heinsen, H., & Korf, H. (2015) · Advances in anatomy, embryology and cell biology · doi:10.1007/978-3-319-19285-7_4 · Cited by 1
1.4 Neuropathologie der Demenzen
(2005) · Thieme eBooks · doi:10.1055/b-0034-22397 · Cited by 1
Pietropaolo, S., Sluyter, F., & Crusio, W. E. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781107360556.030 · Cited by 1
Hiding in Plain Sight-Could a Common Molecular Mechanism Define Neurodegenerative
Rangachari, V. (2013) · Cited by 1
Walia, V., & Garg, M. (2018) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-5225-5282-6.ch014 · Cited by 1
Alzheimer’s Disease Silent Killer of Memory: A Review on Pathological Mechanisms
Singh, S. (2019) · Alzheimer’s & Neurodegenerative Diseases · doi:10.24966/and-9608/100017 · Cited by 1
“Alzheimer’s Disease (AD) is a chronic neurodegenerative disorder that causes degeneration of CNS neurons thereby debilitating symptoms like loss of memory, interrupted speech and inability to carry out daily activities [57].”
BackgroundChen, M., Kretzschmar, D., Verdile, G., & Lardelli, M. T. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415894-8.00025-7 · Cited by 2
Dhénain, M. (2021) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2021.04.018 · Cited by 1
Suppression of amyloid fibril formation by UV irradiation
Matsushita, H., Fukunari, A., Sameshima, G., et al. (2022) · Journal of Radiation Research and Applied Sciences · doi:10.1016/j.jrras.2022.100484 · Cited by 1
Medicinal Herbs Against Central Nervous System Disorders
Tùng, B. T., Hue, N. T., Long, N. V., & Ngoc, N. T. (2023) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-6684-6737-4.ch006 · Cited by 1
Cognitive Aging and the Transition to Early Alzheimer’s Disease
Mormino, E. C., & Jagust, W. J. (2024) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780190917982.013.59 · Cited by 1
Immunopathogenesis of Alzheimer’s disease, Parkinson’s Disease, and other Neurodegenerative Diseases
Kumar, S., Shukla, A. K., Yadav, V. K., Srivastava, A., Dwivedi, D., & Singh, S. P. (2024) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815238754124010006 · Cited by 1
An Alternate View of Neuroprotection with Peptides in Alzheimer’s Disease
King, S. P., & Suphioglu, C. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.91065 · Cited by 1
Mild Cognitive Impairment and Early Dementia
Damasceno, B. P. (2020) · Springer eBooks · doi:10.1007/978-3-030-57267-9_20 · Cited by 1
Graw, J. (2020) · Springer eBooks · doi:10.1007/978-3-662-60909-5_14 · Cited by 1
Linsley, J. W., Shah, K. D., Castello, N. A., Chan, M. Y., Haddad, D., Mancini, J., Oza, V. D., Wang, S., Javaherian, A., Kokel, D., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/726588 · Cited by 1
Pal, S., & Melnik, R. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.27.433219 · Cited by 1
Wang, Z., Shu, H., Liu, D., Su, F., Xie, C., Cui, Z., & Zhang, Z. (2020) · doi:10.21203/rs.3.rs-31020/v2 · Cited by 1
“Importantly, previous network ndings in AD provide the strongest support for the “transneuronal spread model”, in which AD pathology propagates along target network connections once the disease has spread throughout the “hub” regions [29, 30].”
BackgroundWilson, D. L., Carreon, A., Chinnam, S., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4164618/v1 · Cited by 1
“Measurement of the rate can then be used to ne-tune ambient conditions either to intervene in the �brillation or to promote it (say, for biophysical studies) (9).”
BackgroundSimonetti, F., Zhong, W., Hutten, S., Uliana, F., Schifferer, M., Rezaei, A., Ramirez, L. M., Hochmair, J., Sankar, R., Gopalan, A. B., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.07.662960 · Cited by 1
Graw, J. (2015) · Springer eBooks · doi:10.1007/978-3-662-44817-5_14
The dynamic nature of amyloid-beta protein aggregation and its association to Alzheimer’s disease
Vilaprinyó-Pascual, S. (2015) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya)
Roles of manganese and protein kinase signaling in cell culture and animal models of prion disease
Martin, D. P. (2013) · Iowa State University Digital Repository (Iowa State University) · doi:10.31274/etd-180810-721
“…Alzheimer’s disease, and amyotrophic lateral sclerosis, respectively, can catalyze the conversion from their endogenous conformation to their disease isoforms and can therefore be considered prions (Jucker and Walker, 2011; Lee et al., 2010; Moreno-Gonzalez and Soto, 2011; Walker and LeVine, 2012).”
BackgroundAccumulation of Abnormally Processed Tau Protein in Neuronal Cells as a Biomarker for Dementia
Luna-Muoz, J., Martnez-Maldonado, A., Ibarra-Bracamontes, V., Ontiveros‐Torres, M. Á., Ferrer, I., Florán, B., Cárdenas‐Aguayo, M. D. C., Mena, R., & Meraz‐Ríos, M. A. (2014) · InTech eBooks · doi:10.5772/58305
“This new approach to understanding AD pathol‐ ogy in terms of protein seeding had been proposed by several groups [46-48], however, since 1993, the group of Novak [43], had already called the PHFcore as "tauon", considering its prion like behaviour.”
MethodMarine Natural Products for Protein Misfolding Modulation
James, C., & Vanya, K. (2013) · InTech eBooks · doi:10.5772/54585
“Furthermore, templating is inferred by observation of their spatial spread from select foci in the brain [5, 15, 16].”
BackgroundExpression and characterisation of cardiovascular amyloid proteins
Davies, H. A. (2013) · doi:10.17638/00012075
Takahashi, T. (2014) · Chemistry Letters · doi:10.1246/cl.140883
Epigenomics in Neurobehavioral Diseases
Smith, C. L., & Huang, K. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-388415-2.00007-x
Síntese de um potencial inibidor da B-secretase e sua interação com o enzima
Pereira, R. A. G. (2012) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
HIV-1 Tat Protein Promotes Amyloid β Generation and Tau Phosphorylation in Rat Hippocampal Slices
Lee, E. O., Jhang, K. A., An, Y. W., Ju, W., & Chong, Y. H. (2014) · Journal of Bacteriology and Virology · doi:10.4167/jbv.2014.44.1.102
“disease initiated in neurons by misfolding and aggregation of two specific proteins, Aβ and Tau, which in later stages of disease form the characteristic lesions of Aβ-containing senile plaques, usually surrounded by reactive astrocytes, activated microglia and dystrophic neuritis, and intracellular neurofibrillary ta…”
BackgroundEthical Perspectives on Stem Cell-based Cellular Therapies for Neurodegenerative Diseases
Ebbesen, M. (2012) · Journal of Cell Science & Therapy · doi:10.4172/2157-7013.s3-003
“Thus, it would be necessary to impede the seeding cascade of Aβ for cellular therapies to be effective against AD [18,19].”
BackgroundIslet amyloid polypeptide (IAPP) in Type 2 diabetes and Alzheimer disease
Oskarsson, M. E. (2015) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
D-Leucine Suppresses Prion Formation in Prion-Infected Culture Cells
Miyashita, K. (2014) · International Journal of Neurology and Neurotherapy · doi:10.23937/2378-3001/1/1/1011
“A rapidly expanding body of evidence also indicates that prions cause many different neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases as well as the frontotemporal dementias and some forms of amyotrophic lateral sclerosis (ALS) [7,8].”
BackgroundUBB+1, an important switch in the onset of Alzheimer’s disease
Gentier, R. J. G. (2015) · Research Publications (Maastricht University) · doi:10.26481/dis.20151105rg
Dynamics of amyloid plaque formation in Alzheimer’s Disease
McCarter, J. F. (2014) · Elektronische Hochschulschriften der LMU München (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.17434
Rüb, U., Vonsattel, J. P., Heinsen, H., & Korf, H. (2015) · Advances in anatomy, embryology and cell biology · doi:10.1007/978-3-319-19285-7_8
The Disease Protein Huntingtin and Neuronal Protein Aggregations in Huntington’s Disease (HD)
Rüb, U., Vonsattel, J. P., Heinsen, H., & Korf, H. (2015) · Advances in anatomy, embryology and cell biology · doi:10.1007/978-3-319-19285-7_9
Amyloid Beta Aggregates in Alzheimer's Disease Are Prions, Study Finds
Talan, J. (2012) · Neurology Today · doi:10.1097/01.nt.0000417963.62525.f7
The Use of Microfluidic-based Neuronal Cell Cultures to Study Alzheimer's Disease
Meissner, R., & Renaud, P. (2014) · Royal Society of Chemistry eBooks · doi:10.1039/9781849737593-00057
Molecular Imaging in Alzheimer Clinical Trials
Schmidt, M. E., Matthews, D. C., & Staelens, S. G. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00020-4
Propagation and Replication of Misfolded SOD1: Implications for Amyotrophic Lateral Sclerosis
Bertolotti, A. (2013) · Research and perspectives in Alzheimer's disease · doi:10.1007/978-3-642-35491-5_9
“Similar observations have been reportedwith diverse proteins associatedwith neurodegenerative diseases (Jucker and Walker 2011).”
ResultGene–Environment Interactions in Huntington’s Disease
Bichell, T. J., Uhouse, M. A., Bradley, E. M., & Bowman, A. B. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800228-5.00017-0
Protein-Inspired Synthetic Biology: New Forms for Old Functions
Ryadnov, M. G. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12552-1
Johnson, L. G. (2012) · UWA Profiles and Research Repository (UWA)
Singh, O. (2017) · Scholarship@Western (Western University)
Phillips, E. C. (2017) · Research Portal (King's College London)
Fibril branching dominates self-assembly of mutant huntingtin exon-1 aggregates in vitroPreprint
Wagner, A. S., Politi, A. Z., Steinhof, A., et al. (2017) · MDC Repository (Max-Delbrueck-Center for Molecular Medicine)
Patent Highlights April–May 2018
Mucke, H. A. (2018) · Pharmaceutical Patent Analyst · doi:10.4155/ppa-2018-0022
Begcevic, I. (2018) · TSpace (University of Toronto)
Igel‐Egalon, A., Laferrière, F., Moudjou, M., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/583781
“In terms of pathogenic mechanisms, the prion paradigm unifies a number of age-related, 51 incurable neurodegenerative disorders that are caused by protein misfolding and aggregation 52 [13,21,22,9].”
BackgroundShafiq, M. (2019) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-7266
Kang, S. S., Liu, X., Ahn, E. H., Xiang, J., Manfredsson, F. P., Yang, X., Luo, H. R., Liles, L. C., Weinshenker, D., & Ye, K. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/688200
“The progression of AD pathology follows a remarkably systematic pattern across individuals, and aberrant forms of Tau are capable of neuron-to-neuron propagation via a prion-like process of corruptive templating (15).”
BackgroundDhénain, M. (2015) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)30893-3
“De plus, les noyaux d’amyloïde semblent pouvoir migrer à distance de leur site de production en suivant, par exemple, les voies anatomiques [53].”
How would defining Parkinson’s as a prion disease impact the search of a cure?
Scialò, C., & Legname, G. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1753504
A Model Of Agitated Behavioral Symptoms In Persons With Alzheimer Disease
Kero, K. (2020) · Human Biology
The effect of electricity on the interaction between $\mathrm{A}\beta$ and lipid bilayer by AFM
Pan, Y., & Wang, Y. (2021) · IEEE International Conference on Manipulation, Manufacturing and Measurement on the Nanoscale (3M-NANO) · doi:10.1109/3m-nano49087.2021.9599735
Hydrogels based on short amphipathic peptides: self-assembly studies and apllications
Tena‐Solsona, M. (2015) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya) · doi:10.6035/14002.2015.177169
Barker, R. A., & Drouin‐Ouellet, J. (2013) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.718028152.793481500
Walia, V., & Garg, M. (2020) · IGI Global eBooks · doi:10.4018/978-1-7998-3441-0.ch002
Ebenezer, I. S. (2015) · Wiley eBooks · doi:10.1002/9781118385777.refs
Béringue, V. (2015) · Reviews in Cell Biology and Molecular Medicine · doi:10.1002/3527600906.mcb.200400151.pub2
Hillert, D. G. (2017) · Springer eBooks · doi:10.1007/978-3-658-20113-5_12
Hillert, D. G. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0609-3_11
Petersen, R. B. (2012) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.717955044.793460387
Rüb, U., Vonsattel, J. P., Heinsen, H., & Korf, H. (2015) · Advances in anatomy, embryology and cell biology · doi:10.1007/978-3-319-19285-7_11
Donnelly, D. P. (2019) · Digital Repository Service (Northeastern University) · doi:10.17760/d20316343
Zerr, I. (2016) · Springer-Lehrbuch · doi:10.1007/978-3-662-46892-0_22
Wang, Z., Shu, H., Liu, D., Su, F., Xie, C., Cui, Z., & Zhang, Z. (2020) · doi:10.21203/rs.3.rs-31020/v1
Uncovering systems-level molecular similarities between Alzheimer’s and Parkinson’s diseasesPreprint
Fallahi, H., Yadegari, Z. S., & Radak, M. (2023) · Research Square · doi:10.21203/rs.3.rs-2454477/v1
Ahlawat, J., Wilson, D. L., Carreon, A., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2631727/v1
Aksic, M., Bankovic, I., Jakovčevski, I., Mojsoska, A., Stankovic, S., & Vulović, M. (2023) · EABR. Experimental and Applied Biomedical Research · doi:10.2478/sjecr-2023-0003
The ubiquitin-proteasome system in neurodegenerative diseases
Verheijen, L. (2023) · Research Publications (Maastricht University) · doi:10.26481/dis.20231024lv · Cited by 1
(2000) · Time to knit · doi:10.1016/s9999-9994(17)70004-9
(2000) · Time to knit · doi:10.1016/s9999-9994(17)70001-3
Jiang, S., Tian, Y., Li, H., Liu, T., Chen, J., Pei, H., Yao, Y., Ye, G., Liao, J., Wang, Y., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5132611
Makovitzky, J. (2025) · Springer eBooks · doi:10.1007/978-3-031-70714-8_8
Karatzetzou, S., Ioannidis, S., Konstantinopoulou, E., Parissis, D., Afrantou, T., & Ioannidis, P. (2025) · Biomolecules · doi:10.3390/biom15040522 · Cited by 1
“Among other pathologically aggregated proteins with seeding and propagation properties termed proteopathic seeds, A β has proven to be transmissible experimentally both in vitro and in animal models [30–32].”
Florio, D., Manna, S. L., Fiore, G. R., et al. (2025) · ChemBioChem · doi:10.1002/cbic.202500306
Brennan, G. S., Thompson, T., Oliveri, H., Vinje, V., Ringstad, G. A., Eide, P. K., Goriely, A., & Rognes, M. E. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.03.657596
Yu, R., Li, Y., Cao, Y., Kong, Z., Zhou, Y., Hou, B., & Xie, A. (2025) · BMC Medical Genomics · doi:10.1186/s12920-025-02280-8
“A hallmark of neurodegenerative diseases is the accumulation of pathological protein aggregates in vulnerable brain regions, with cross-pathology observed across disorders [2, 3].”
Metadata
- Authors
- Jucker, M., & Walker, L. C.
- Affiliations
- Emory University (US)
- Corresponding author
- Jucker, Mathias
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2011-10
- Volume
- 70
- Issue
- 4
- Pages
- 532-540
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- PMC
- PMC3203752
- OpenAlex
- W2018852249
- Semantic Scholar
- a083431598aa8300a06d560a5e6377c2d187348a
- Cited by
- 622
- References
- 111
- Citations by year
- 2026: 9 · 2025: 22 · 2024: 16 · 2023: 26 · 2022: 30 · 2021: 25 · 2020: 45 · 2019: 47 · 2018: 39 · 2017: 47 · 2016: 46 · 2015: 63 · 2014: 58 · 2013: 85 · 2012: 57
- FWCI
- 7.06
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Annals of Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- DZNE Pub (submittedVersion)
- Funders
- U.S. Public Health Service (NCRR RR-00165)
- National Institute on Aging (P01AG026423, P50AG025688)
- National Center for Research Resources (P51RR000165)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Prion Diseases and Protein Misfolding
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, amyloid-beta, tau protein, prion-like propagation, protein aggregation, neurodegenerative diseases, frontotemporal lobar degeneration, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, alpha-synuclein, TDP-43, superoxide dismutase 1, huntingtin, amyloid seeding, diagnostic biomarkers
- MeSH terms
- Alzheimer Disease, Animals, DNA-Binding Proteins, Humans, Prions, Proteins, Amyloid beta-Peptides, tau Proteins, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
